Agroton Public Ltd (0QH1) News

Form DEF 14A - Other definitive proxy statements

Form 8-K - Current report

SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates

MIAMI, May 20, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the “Company”), a...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

SAB Biotherapeutics Appoints Jay Skyler, MD, to the Board of Directors

MIAMI, May 06, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a...

SAB Biotherapeutics Provides SAB-142 Trial Update

MIAMI BEACH, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the...

SAB Biotherapeutics to Present at INNODIA Annual Meeting

MIAMI BEACH, Fla., April 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the...

SAB Biotherapeutics to Present at the Needham Virtual Healthcare Conference

Miami, FL , April 04, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the...

SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results

Sioux Falls, SD , March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year 2023 Operating and...

SAB Biotherapeutics Announces Clinical Partnership with Naval Medical Research Center to Advance Potential Influenza Treatment

SIOUX FALLS, S.D., March 25, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the...

SAB Biotherapeutics to Present at the BIO CEO & Investor Conference

SIOUX FALLS, S.D., Feb. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the...

SAB Biotherapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

SIOUX FALLS, S.D., Feb. 08, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the...

SAB Biotherapeutics Announces Executive Leadership Change

SIOUX FALLS, S.D., Feb. 02, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (“SAB” or the...

SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

SIOUX FALLS, S.D., Jan. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), (SAB), a...

SAB Biotherapeutics Announces 1-for-10 Reverse Stock Split

SIOUX FALLS, S.D., Jan. 02, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), a...